In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23% at 24 months compared to enzalutamide in patients with metastatic ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the ...

Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

The pharmaceutical company has received tentative approval from the USFDA to manufacture Enzalutamide tablets in 40 mg and 80 ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

Maruti Suzuki reported a nearly 2% jump in September total sales at 1,84,727 units versus 1,81,343 units in the corresponding ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...